Diamyd Medical AB
Company Profile
Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWET: +46 86610026
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
45
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.40 | 33.20 | -0.37% |
| CAC 40 | 8,364.65 | 25.69 | 0.31% |
| DAX 40 | 25,114.25 | 47.16 | 0.19% |
| Dow JONES (US) | 52,498.64 | 138.37 | -0.26% |
| FTSE 100 | 10,498.29 | 1.00 | 0.01% |
| HKSE | 23,979.30 | 234.42 | -0.97% |
| NASDAQ | 25,873.18 | 408.43 | -1.55% |
| Nikkei 225 | 67,293.53 | 50.80 | 0.08% |
| NZX 50 Index | 13,627.28 | 95.92 | -0.70% |
| S&P 500 | 7,515.34 | 60.05 | -0.79% |
| S&P/ASX 200 | 8,772.20 | 31.50 | -0.36% |
| SSE Composite Index | 3,902.92 | 10.87 | -0.28% |